Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05229341 · ClinicalTrials.gov registry record · NA

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

A NA study of Thyroid Gland Carcinoma, sponsored by City of Hope Medical Center.

Recruiting
Registry status
NA
Development phase
1,450
Enrollment target
1
Study location

NCT05229341: Recruiting NA study of Thyroid Gland Carcinoma, sponsored by City of Hope Medical Center.

NCT05229341 is a NA study of Thyroid Gland Carcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 1,450 participants, above the 314-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (362% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05229341, a NA study of Thyroid Gland Carcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
NA
Development phase
1,450 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

Primary Outcome

The sensitivity of DDMS-2 will be estimated by taking the ratio of the number of true thyroid cancer specimens diagnosed as cancer by DDMS and the total number of thyroid cancer specimens. Will also determine the 95% confidence intervals.

Conditions Studied

Interventions

  • OTHER Electronic Health Record Review
  • PROCEDURE Diagnostic Procedure
  • PROCEDURE Needle Biopsy

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 1,450 participants
Start Date 2021-10-22
Est. Completion 2026-10-22
Phase NA
City of Hope Medical Center

582 total trials

What NCT05229341 shows while recruiting

NCT05229341 is an interventional study that assigns participants to a tested intervention. Its 1,450 participants enrollment target places it among the larger protocols in the corpus, above the 314-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (362% higher).

The record links to 1 condition, with Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Electronic Health Record Review is the first listed.

NCT05229341 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05229341 about?

NCT05229341 is a clinical study titled "Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules". This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to de...

What is the current status of trial NCT05229341?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,450 participants. The study started on 2021-10-22. Estimated completion is 2026-10-22.

What conditions does trial NCT05229341 study?

This clinical trial studies the following conditions: Thyroid Gland Carcinoma.

What interventions are being tested in trial NCT05229341?

The interventions under investigation include: Electronic Health Record Review (OTHER), Diagnostic Procedure (PROCEDURE), Needle Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT05229341?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05229341 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thyroid Gland Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05910268 · 1,450 participants · NA

    Peru Decentralized HIV Care

  • NCT06305312 · 1,450 participants · NA

    Community Services Navigation to Advance Health Equity in Breast Cancer Screening

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05229341, the US trial registry maintained by the National Library of Medicine. NCT05229341 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.